This bill amends Section 379B of the Public Health Service Act to change the program’s appropriation language and add a five‑year authorization of $33,009,000 per year for fiscal years 2027–2031. It also amends Section 2(g) of the Stem Cell Therapeutic and Research Act of 2005 to extend the statutory deadline for the cord blood inventory program from 2026 to 2031.
The changes are narrowly focused: they convert a one‑line appropriation reference into a continuing authorization at a slightly higher annual level and push the cord blood inventory authorization window five years forward. For stakeholders involved in public cord blood banking, stem cell donor registries, and transplant logistics, the bill signals multi‑year funding stability and an extended policy horizon for federal support of cord blood inventory activities.
At a Glance
What It Does
The bill amends 42 U.S.C. 274m to add an explicit authorization of $33,009,000 for each fiscal year 2027 through 2031 while preserving the previously listed $31,009,000 figure. It separately amends the Stem Cell Therapeutic and Research Act of 2005 to change the statutory expiration for the cord blood inventory requirement from 2026 to 2031.
Who It Affects
Entities that operate or receive federal support under the C.W. Bill Young Cell Transplantation Program—including public cord blood banks, donor registries, and program contractors named in the underlying statutes—will see a multi‑year authorization and an extended planning horizon. Federal program managers responsible for administering 42 U.S.C. 274m will need to adjust budget requests and program timelines accordingly.
Why It Matters
A defined multi‑year authorization reduces near‑term funding uncertainty for inventory planning and recruitment activities but does not itself appropriate funds. The extension of the cord blood inventory authority keeps federal policy support in place through 2031, which affects supply strategies for transplantable units and long‑term program contracting.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill makes two targeted statutory edits. First, it revises the appropriation language in the Public Health Service Act provision that authorizes the C.W.
Bill Young Cell Transplantation Program. Rather than a single appropriation line, the amendment inserts two enumerated paragraphs: one restating a $31,009,000 figure and the second explicitly authorizing $33,009,000 for each fiscal year 2027–2031.
That change transforms the statutory text to reflect an ongoing, multi-year funding authorization at a slightly higher level than the prior figure.
Second, the bill amends Section 2(g) of the 2005 Stem Cell Therapeutic and Research Act to extend the statutory date tied to the cord blood inventory program from 2026 to 2031. Practically, this moves the deadline or expiration date embedded in the statute forward five years, preserving the legislative authority for federal engagement in building and maintaining a public cord blood inventory through 2031.These edits are procedural and programmatic rather than program‑expanding: the bill authorizes levels of funding and extends an existing statutory period but does not alter eligibility criteria, reporting requirements, or program missions contained in the underlying statutes.
Because the text amends authorization language, it signals Congress’s intent about future funding levels and program duration but will still require appropriation action to make dollars available and program managers to request and allocate funds accordingly.Operationally, the bill provides a clearer, multi‑year planning baseline for entities that recruit donors, bank cord blood units, or operate transplantation registries. That planning window matters for multi‑year contracts, inventory build targets, and recruitment campaigns, but the statute does not itself create new program authorities or new spending mechanisms beyond the listed dollar amounts and extended dates.
The Five Things You Need to Know
The bill amends 42 U.S.C. 274m (Section 379B of the Public Health Service Act) to change the appropriation language for the C.W. Bill Young Cell Transplantation Program.
It explicitly authorizes $33,009,000 for each fiscal year 2027 through 2031 while retaining a $31,009,000 figure in the statutory text.
Section 2(g) of the Stem Cell Therapeutic and Research Act of 2005 is amended to replace the year "2026" with "2031," extending the cord blood inventory authority five years.
The statutory edits are authorizations in the statute; they do not themselves appropriate funds—separate appropriation action is still required to expend federal dollars.
The bill does not change program scope, eligibility, or reporting requirements in the underlying statutes—its effects are limited to funding authorization and the statutory timeline for cord blood inventory.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the Act’s short title as the "Stem Cell Therapeutic and Research Reauthorization Act of 2025." This is a formal drafting provision that has no substantive programmatic effect but signals the bill’s purpose: to reauthorize and adjust provisions of existing stem cell legislation.
Authorize multi‑year funding for the C.W. Bill Young Program
This provision strikes a prior one‑line appropriation reference and replaces it with numbered paragraphs that (1) restate the $31,009,000 figure and (2) add an explicit authorization of $33,009,000 for each fiscal year 2027 through 2031. Mechanically, that converts the statute from a static appropriation citation into a continuing authorization structure. Practically, it provides Congress’s express authorization level for five fiscal years, which can guide administrative budget requests and program planning; it does not itself transfer money to agencies.
Extend cord blood inventory statutory period
This short amendment replaces the year "2026" with "2031" in the provision governing the cord blood inventory. The change extends the statutory timeframe during which the federal government can pursue policies and funding related to building and maintaining a public cord blood inventory. The amendment preserves existing statutory language and authority but lengthens the period for which that authority remains operative.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Public cord blood banks — They gain an extended planning horizon (through 2031) for inventory development, which supports multi‑year recruitment and banking strategies tied to federal support expectations.
- Transplant candidates (including patients needing hematopoietic stem cell transplants) — Stable, authorized funding and an extended inventory authority increase the likelihood that public supplies of cord blood units will be maintained, preserving access to alternative graft sources.
- Registry and program contractors operating under the C.W. Bill Young provisions — The multi‑year authorization supports contract continuity and budget forecasting for organizations that coordinate donor recruitment and unit distribution.
Who Bears the Cost
- Federal budget/appropriators — Although the bill authorizes $33,009,000 per year for 2027–2031, appropriators must allocate those dollars; the authorization increases baseline pressure on discretionary health budgets.
- Program administrators — Agencies or contractors administering the program will need to adjust multi‑year plans, reporting, and procurement practices to align with the new authorization and extended timeline, which carries administrative workload.
- Other discretionary health programs — If appropriators fund the authorized amounts, they may need to offset costs within constrained budgets, creating indirect trade‑offs for other programs funded from the same appropriations accounts.
Key Issues
The Core Tension
The central dilemma is between providing predictable, multi‑year authorization to support long‑term inventory and recruitment planning and the reality that authorization does not equal appropriation; Congress can signal support without actually funding the program at the authorized level, leaving program implementers with uncertain resources while transplant candidates and cord blood banks plan around an extended but potentially underfunded timeline.
Two implementation and policy issues stand out. First, the bill sets out authorization levels but does not appropriate funds; the practical effect depends on future congressional appropriations.
Authorized figures are useful for planning, but agencies cannot obligate or spend the additional amounts without appropriation action and any applicable budget scoring. Second, the extension of the cord blood inventory authority through 2031 preserves statutory permission to pursue inventory activities but does not change program scope, nor does it specify additional funding for the inventory.
That creates a potential mismatch: programs may be required or expected to maintain inventory authority without a commensurate, guaranteed funding stream.
Additional unresolved questions include how agencies will integrate the modest funding increase into recruitment, testing, and storage pipelines, and whether the $33,009,000 level materially changes capacity given existing program costs. The statute does not amend reporting, outcome metrics, or eligibility rules, so tracking the effectiveness of the extended authorization will depend on existing reporting frameworks.
Finally, because the change is an authorization, administrative timing matters: program managers and contractors should treat the amendment as a policy signal but await appropriation language and timing before committing to expanded multi‑year activities.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.